Ancilia Biosciences

Ancilia Biosciences is a biotechnology company focused on harnessing the natural power of CRISPR to create bacterial therapies and products with immunity against destructive viruses. The company's mission is to overcome the challenges of the virome, the collection of viruses within a specific environment, by leveraging the natural immune system of bacteria, CRISPR-Cas. Ancilia's two proprietary platforms, CoVE™ and EPIC™, work in tandem to identify and characterize viruses, and then engineer bacteria with CRISPR-mediated immunity to these viruses. This unique approach has the potential to significantly increase the efficacy and utility of live bacterial products for a wide range of applications in healthcare, agriculture, and industrial biotechnology.

Ancilia Biosciences is a young company, headquartered in New York City, with a team of scientists and advisors who are leaders in the fields of CRISPR and the virome. Their work is rooted in the pioneering discoveries of co-founder Dr. Rodolphe Barrangou, who established the natural function of CRISPR in bacteria, and co-founder and chief technology officer David Paez-Espino, PhD, a leading expert in virology and bioinformatics. With recent funding from Safar Partners and other investors, Ancilia is rapidly advancing its technologies and is poised to become a major player in the field of microbiome-based therapeutics.

Ancilia Biosciences is a biotechnology company leveraging the natural power of CRISPR to create beneficial bacterial products with immunity against destructive viruses. They believe that viruses can limit the effectiveness of beneficial bacteria, and their mission is to address this issue by harnessing the CRISPR-Cas system, nature's first immune system, to "vaccinate" bacteria against these viruses. Their innovative platforms aim to unlock the full potential of bacteria as therapies and products across various industries, including therapeutics, agriculture, and industrial biotechnology.

Ancilia Biosciences promotes a culture of innovation and collaboration, driven by a passion for scientific discovery. They value a diverse team of passionate, curious and committed scientists who are dedicated to tackling the virome through the power of CRISPR. This is reflected in their team, which includes both industry veterans and academic collaborators working together to advance their platforms and create virus-resistant live bacterial products for a range of applications.

Ancilia Biosciences does not explicitly mention diversity, equity, and inclusion (DEI) on its website, so there is no information about the company's approach to DEI.